Lionheart Longevity News
Lionheart Health Announces Clinical Results Supporting Brain Band™ and BodStim™ Programs for Brain Health and Healthy Aging
Clinical programs combine bioelectric signaling, neuromuscular stimulation and regenerative-health technologies designed to support cognition, physical performance and healthy aging HUNTINGTON…
Lionheart Health Announces Positive Clinical Trial Results for ErectiStim™ Male Sexual Wellness Bioelectric Therapy Platform
Five Clinical Studies Demonstrate Improvements in Male Sexual Wellness and Erectile Function as Lionheart Expands into Multi-Modality Regenerative Male Health…
Lionheart Health Announces Encouraging BladderCell™ Clinical Results and Expands Regenerative Bladder & Pelvic Health Platform with B-Alive™, PelvicStim™, and Next-Generation Implantable Bioelectric Therapy
Clinical Program in Brazil Demonstrates Encouraging Improvements in Bladder Function While Company Advances Wearable, Regenerative, and Implantable Technologies HUNTINGTON BEACH,…
Praise for Xprize Healthspan on Top 20 Finalists Reveal Day
There are moments in history when the way we solve problems matters just as much as the problems themselves. And…
The “Arterial Cement” Problem: A Multi-Modal Strategy for Healthier Blood Pressure and Vascular Aging
Why Lionheart Health’s PressureStim™, Electro-Acupuncture, BodStim™ Exercise and Klotho-Up USA Program Target More Than a Number on a Blood-Pressure Cuff…
Leonhardt Ventures Announces Provisional Patent Application for Combination Osteoarthritis Therapy Featuring Pentadeca Arginate (PDA+) Licensed to Lionheart Health’s OrthoStim™ Platform
New investigational study arm to evaluate multimodality regenerative approach for joint health, mobility, inflammation, and healthy aging Huntington Beach, California…
Lionheart Health Announces Positive Pilot Clinical Trial Results for PressureStim™ Investigational Wellness Technology
Independent randomized clinical study demonstrates significant blood pressure reductions with sensory electrical stimulation applied over the kidney region HUNTINGTON BEACH,…
Lionheart Health Launches New Hepatocyte Growth Factor (HGF) Studies as Part of its Klotho-Up™ Longevity Protocol
IRVINE, California — July 28, 2026 — Lionheart Health, Inc. today announced the launch of new clinical and translational research evaluating hepatocyte growth factor…
Leonhardt Ventures LLC, Lionheart Health, and CancerCell Prepare Provisional Patent Application for Bioelectric Expression of Thymulin Across Multiple Therapeutic Applications
Huntington Beach, California – July 28, 2026 — Leonhardt Ventures LLC, in collaboration with Lionheart Health, Inc. and CancerCell, Inc., today announced the preparation of…
The Next Decade of Healthy Longevity: Why Technology May Become the Primary Driver of Healthspan Extension
A Forward-Looking Perspective Over the past century, improvements in life expectancy have been driven primarily by sanitation, vaccines, nutrition, and…
Lionheart Health and Leonhardt Ventures File Provisional Patent Covering Bioelectric Polylaminin Expression and Multi-Modal Spinal Cord Regeneration
Proposed SpineStim™ research program will evaluate noninvasive targeted bioelectric stimulation and BodStim™ alone and in combination with an injectable regenerative…
Klotho-Based Neuroprotection for Epilepsy and Seizure-Associated Brain Injury
Executive Summary Lionheart Health proposes a translational research initiative to determine whether increasing alpha-Klotho can reduce seizure-associated brain injury, neuroinflammation and cognitive…